Magenta Therapeutics (MGTA) has an average buy rating among analysts, with a price target range of $2 to $20. (MT Newswires covers equity, commodity and...
Magenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
Magenta Therapeutics (MGTA) shares were down almost 10% on Monday afternoon after a series of price-target cuts. Mizuho Securities cut the price target to...
Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
Magenta Therapeutics (MGTA) has an average rating of buy and price targets ranging from $6 to $8, according to analysts polled by Capital IQ. (MT Newswires...
Health care stocks were narrowly lower this afternoon, with the NYSE Health Care Index slipping 0.1% and the SPDR Health Care Select Sector ETF (XLV) down...
Health care stocks were narrowly lower this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) down 0.2%. The...
Magenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $17, according to analysts polled by Capital IQ. (MT...
Magenta Therapeutics (MGTA) said Thursday it is planning to focus capital spending on its ongoing development of MGTA-117 as a potential treatment for...
Magenta Therapeutics (MGTA) has an average rating of Buy and price targets ranging from $6 to $20, according to analysts polled by Capital IQ. (MT...